Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary (ACSD)
- PMID: 36719546
- PMCID: PMC9888338
- DOI: 10.1186/s41687-022-00535-x
Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary (ACSD)
Abstract
Background: Patient-reported outcome measures are needed to assess the impact of treatments for COVID-19 on symptoms. The ACTIV-2 COVID-19 Symptom Diary (ACSD) is being used in the ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines-2 (ACTIV-2) platform clinical trial. The purpose of the current study was to conduct qualitative interviews to assess content validity of the ACSD.
Methods: Interviews were conducted with adults who had tested positive for SARS-CoV-2. The ACSD begins with global items, followed by a symptom checklist. Each interview began with concept elicitation focusing on participant experiences with COVID-19. Then, participants completed the ACSD, and cognitive interviews were conducted to evaluate the questionnaire. Interviews were recorded, transcribed, and coded following a qualitative content analysis. For the qualitative analysis, a coding dictionary was developed with a list of all potential codes and instructions for how the codes should be applied and combined.
Results: Interviews were conducted with 30 participants (mean age = 39 years; 57% female; 17% Latinx; 17% Black/African American; 40% meeting at least one criterion for classification as high risk of progression to severe COVID-19). Commonly reported symptoms included fatigue (reported by 100% of the sample), body pain/muscle pain/aches (87%), headaches (87%), cough (83%), loss of smell (73%), shortness of breath/difficulty breathing (70%), and chills (70%). The 13 symptoms most commonly reported in this study are included in the ACSD. After completing the ACSD, participants consistently reported that it was clear and easy to complete, and all items were generally interpreted as intended. Based on participants' input, the ACSD was edited slightly after the first 13 interviews, and the revised version was used for the final 17 interviews. Two additional items assessing "brain fog" and dizziness were recommended for addition to the ACSD in future research.
Conclusions: This qualitative study supports the content validity of the ACSD for assessment of COVID-19 symptoms. Quantitative research with larger samples will be needed to examine the questionnaire's measurement properties.
Plain language summary
This study focused on the ACTIV-2 COVID-19 Symptom Diary (ACSD), a questionnaire that assesses symptom severity of COVID-19. The ACSD begins with global items assessing overall symptom severity, followed by a symptom checklist focusing on individual symptoms. Interviews were conducted with 30 adults who had tested positive for COVID-19. The patients reported their experiences with COVID-19, completed the ACSD, and provided their opinions about the ACSD. Based on input from these patients, the ACSD appears to be clear and easy to complete, and it includes the most common and important symptoms of COVID-19. The ACSD was edited for clarity, and “brain fog” and dizziness were recommended additions for future research. This study suggests that the ACSD is a useful questionnaire for assessment of COVID-19 symptoms in clinical studies. Studies like this are important for ensuring that symptoms are measured appropriately and accurately in clinical trials. Future research with larger samples will be needed to further examine the questionnaire.
© 2023. The Author(s).
Conflict of interest statement
This qualitative study was funded by Eli Lilly and Company. Authors LSM, KDS, and KSC are employed by Evidera, a company that received funding from Lilly for time spent on this research. Authors ANN and KMM are or were employed by Lilly while this work was conducted. Authors KWC, MDH, and DMS did not receive funding for time spent on this qualitative research.
Figures
Similar articles
-
Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.Am J Kidney Dis. 2017 Oct;70(4):532-540. doi: 10.1053/j.ajkd.2017.04.023. Epub 2017 Jun 26. Am J Kidney Dis. 2017. PMID: 28663063
-
Assessing asthma symptoms in children: qualitative research supporting the development of the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O).J Patient Rep Outcomes. 2023 Oct 20;7(1):104. doi: 10.1186/s41687-023-00639-y. J Patient Rep Outcomes. 2023. PMID: 37863864 Free PMC article.
-
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z. Trials. 2021. PMID: 33419461 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 20;5:CD013665. doi: 10.1002/14651858.CD013665.pub3. PMID: 33620086 Free PMC article. Updated.
-
Developing Patient-Reported Outcome Measures to Assess Side Effects of Cancer Treatment [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Sep. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Sep. PMID: 39250575 Free Books & Documents. Review.
Cited by
-
How can qualitative in-depth interviews optimize cross-cultural measurement of academic resilience?Front Psychol. 2025 Mar 20;16:1444978. doi: 10.3389/fpsyg.2025.1444978. eCollection 2025. Front Psychol. 2025. PMID: 40181895 Free PMC article.
-
Evaluation of the Content Validity of the COVID-19 Symptoms Daily Diary.Patient Relat Outcome Meas. 2025 Jan 17;16:37-53. doi: 10.2147/PROM.S488914. eCollection 2025. Patient Relat Outcome Meas. 2025. PMID: 39839844 Free PMC article.
-
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.J Infect Dis. 2023 Aug 31;228(Suppl 2):S83-S91. doi: 10.1093/infdis/jiad300. J Infect Dis. 2023. PMID: 37650237 Free PMC article. Clinical Trial.
References
-
- Sheikhi K, Shirzadfar H, Sheikhi M. A review on novel coronavirus (COVID-19): symptoms, transmission and diagnosis tests. Trop Med Infect Dis. 2020;2(1):1–8.
-
- Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. doi: 10.1001/jama.2021.0202. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous